Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study

Wu, Hao; Davis, Connie L.; Hirsch, Irl B.; Eng, Lily J.; Daniels, Terri; Walsh, Daniel; Lernmark, Åke

doi:10.1007/s004150050443

Cited by 42 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TPE is an alternative treatment for the patients resistant to other treatments. 10,11,15,16 Our patient had taken benzodiazepines, baclofen, IVIg and methyl prednisone before admitting to our ICU; but all these treatments did not alter his clinical status. He was undertaken to seven sessions of TPE treatment in the ICU; and he produced a good response to this treatment and the clinical and neurophysiological findings improved quite rapidly.…”

Section: Discussionmentioning

confidence: 97%

Therapeutic Plasma Exchange in an Uncommon Disease: Stiff-Person Syndrome: Case Report

Hergünsel¹,

Altun²,

Çukurova³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Therapeutic Plasma Exchange in an Uncommon Disease: Stiff-Person Syndrome: Case Report

Hergünsel¹,

Altun²,

Çukurova³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

“…It has also been observed that some SPS patients respond to treatment with immunomodulatory agents (Vicari 1989;Brashear & Phillips 1991;Hao 1999;. Plasmapheresis has been reported to be beneficial in some SPS patients, and in a case study the improvement of symptoms correlated with decreased GAD65 antibody levels (Dalakas 2009).…”

Section: Gad65 Igg Antibodies and Gad65-specific T Cells In Spsmentioning

confidence: 95%

MS and clinically isolated syndromes: Shared specificity but diverging clonal patterns of virus‐specific IgG antibodies produced in vivo and by CSF B cells in vitro

Skorstad

Vandvik

Vartdal

et al. 2009

Euro J of Neurology

View full text Add to dashboard Cite

Background: Intrathecal synthesis of oligoclonal IgG antibodies against measles virus (MeV), varicella zoster virus (VZV) and herpes simplex virus type‐1 (HSV‐1) is a characteristic feature multiple sclerosis (MS). Methods: We have used isoelectric focusing‐immunoblot to define the clonal patterns of IgG and of IgG antibodies to MeV, VZV and HSV‐1 in supernatants of in vitro cultures of peripheral blood lymphocytes (PBL) and cerebrospinal fluid (CSF) cells and in sera and CSF from three patients with MS and three patients with clinically isolated syndromes (CIS) suspective of demyelinating disease. Results: In vitro synthesis of IgG by PBL was not detected in any patient. In contrast, in vitro synthesis by CSF cells of oligoclonal IgG and oligoclonal IgG antibodies to one or two of the three viruses tested was observed in all six patients. The clonal patterns of the in vitro synthesized IgG and virus specific IgG differed to varying extent from those synthesized intrathecally in vivo. However, in each patient, the in vitro and in vivo intrathecally produced antibodies displayed specificity for the same viruses. The addition of B cell activating factor (BAFF) had no effect on the amounts or clonal patterns of either total IgG or virus‐specific IgG produced by CSF cells in vitro. Conclusion: Virus specific B cells capable of spontaneous IgG synthesis are clonally expanded in the CSF of patients with MS. The B‐cell repertoire in CSF samples is only partially representative of the intrathecal B‐cell repertoire.

show abstract

“…Corticosteroids have been successful in some patients with SPS 4 , but no controlled trial has been conducted to date. Benefit in individual cases with immunosuppressive agents such as rituximab, azathioprine, methotrexate, cyclophosphomide and mycophenolate mofetil have been reported but these drugs have not been validated systematically 16,17 .…”

Section: Stiff Person Syndromementioning

confidence: 99%

Pathogenicity of autoantibodies in neurological disorders

Chang

2014

J of Cey Coll of Phy

View full text Add to dashboard Cite

Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study

Cited by 42 publications

References 27 publications

Therapeutic Plasma Exchange in an Uncommon Disease: Stiff-Person Syndrome: Case Report

Therapeutic Plasma Exchange in an Uncommon Disease: Stiff-Person Syndrome: Case Report

MS and clinically isolated syndromes: Shared specificity but diverging clonal patterns of virus‐specific IgG antibodies produced in vivo and by CSF B cells in vitro

Pathogenicity of autoantibodies in neurological disorders

Contact Info

Product

Resources

About